Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants

  • Eiger BioPharmaceuticals Inc EIGR announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association Scientific Session.  
  • HI is an ultra-rare, life-threatening pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.  
  • Avexitide significantly reduced glucose infusion rate (GIR) when evaluated across dose levels, with dose-dependent improvements observed.  
  • Avexitide 100, 200, and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in GIR relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.  
  • Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.
  • The company plans to be Phase 3 ready as early as 2022.
  • Price Action: EIGR shares are up 7.9% at $9.36 during the market session on the last check Monday.

Posted In: BriefshyperinsulinismNewsHealth CareSmall CapGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.